ImmunityBio, Inc. (IBRX) shares jumped about 24% in premarket trading after the company said enrollment in its QUILT-2.005 bladder cancer trial exceeded expectations and is over 85% complete. Full enrollment is expected by Q2 2026, with plans to submit a biologics license application by the end of 2026.